1. Home
  2. ORIC

as 06-20-2025 3:39pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Founded: 2014 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 362.9M IPO Year: 2020
Target Price: $18.83 AVG Volume (30 days): 2.0M
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.88 EPS Growth: N/A
52 Week Low/High: $3.90 - $14.67 Next Earning Date: 08-11-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ORIC Daily Stock ML Predictions

Stock Insider Trading Activity of Oric Pharmaceuticals Inc. (ORIC)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Piscitelli Dominic ORIC Chief Financial Officer Jun 6 '25 Sell $10.00 2,900 $29,021.32 104,164

Share on Social Networks: